Treatment that follows guidelines closely dramatically improves overall survival of patients with anal canal and margin cancers
Menée sur 155 patients atteints d'un cancer du canal anal ou de la marge anale (durée médiane de suivi : 50,7 mois), cette étude montre que les traitements respectant de manière drastique les recommandations de trois sociétés savantes européennes (European Society for Medical Oncology, European Society for Radiotherapy & Oncology, European Society of Surgical Oncology) améliorent la survie globale des patients
Background : To assess relevance of ESMO-ESSO-ESTRO treatment guidelines in a retrospective analysis of patients with anal canal or anal margin cancers. Material and methods : 155 patients were separated into standard treatment group (STG), treated according to or closely the guidelines, and an altered treatment group (ATG). Results : The median follow-up time was 50.7 months. In the STG, the 5- and 10-year LR-DFS rates were 75.2% and 72.7%; in the ATG, they were 66.8% and 61.2%, respectively. In the STG, the 5- and 10-year OS rates were 81.8% and 68%; in the ATG, they were 63.3% and 49.5%, respectively (p = 0.037). In the multivariate analysis, favorable prognostic factors for OS included the standard treatment, age <60, tumor < T3, no HIV infection and a total radiation dose >50.4 Gy. Conclusion : This study identifies the superiority of treatment according to standard guidelines compared to altered treatment. Our results corroborate the guidelines.
http://www.sciencedirect.com/science/article/pii/S1040842816300427